Yao Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1413535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. Scientific Reports, 2015, 5, 7654.	3.3	140
2	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. European Urology, 2018, 73, 322-339.	1.9	130
3	Epidemiology and genomics of prostate cancer in Asian men. Nature Reviews Urology, 2021, 18, 282-301.	3.8	111
4	Prostate cancer in East Asia: evolving trend over the last decade. Asian Journal of Andrology, 2015, 17, 48.	1.6	90
5	Inactivation of the AMPK–GATA3–ECHS1 Pathway Induces Fatty Acid Synthesis That Promotes Clear Cell Renal Cell Carcinoma Growth. Cancer Research, 2020, 80, 319-333.	0.9	90
6	The prognostic significance of p53, Kiâ€67, epithelial cadherin and matrix metalloproteinaseâ€9 in penile squamous cell carcinoma treated with surgery. BJU International, 2007, 100, 204-208.	2.5	87
7	Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. Cancer Research, 2019, 79, 2604-2618.	0.9	87
8	Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nature Genetics, 2020, 52, 908-918.	21.4	77
9	Adjuvant chemotherapy is associated with improved overall survival in pelvic node–positive penile cancer after lymph node dissection: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 496.e17-496.e23.	1.6	76
10	Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumor Biology, 2015, 36, 8537-8543.	1.8	71
11	Predicting Pelvic Lymph Node Metastases in Penile Cancer Patients: A Comparison of Computed Tomography, Cloquet's Node, and Disease Burden of Inguinal Lymph Nodes. Onkologie, 2008, 31, 37-41.	0.8	65
12	A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. European Urology, 2019, 75, 558-561.	1.9	64
13	Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU International, 2015, 116, 196-201.	2.5	62
14	Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 222-230.	7.3	61
15	Visceral Obesity and Risk of High Grade Disease in Clinical T1a Renal Cell Carcinoma. Journal of Urology, 2013, 189, 447-453.	0.4	58
16	MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer. PLoS ONE, 2015, 10, e0124410.	2.5	58
17	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clinical Cancer Research, 2020, 26, 4551-4558.	7.0	49
18	Frozen sectionâ€guided wide local excision in the treatment of penoscrotal extramammary Paget's disease. BJU International, 2007, 100, 1282-1287.	2.5	47

#	Article	lF	CITATIONS
19	Development and Evaluation of a Nomogram to Predict Inguinal Lymph Node Metastasis in Patients With Penile Cancer and Clinically Negative Lymph Nodes. Journal of Urology, 2010, 184, 539-545.	0.4	46
20	Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3. Cancer Research, 2016, 76, 3277-3284.	0.9	46
21	Surgical management of penile carcinoma <i>in situ</i> : results from an international collaborative study and review of the literature. BJU International, 2018, 121, 393-398.	2.5	45
22	SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Journal of Experimental and Clinical Cancer Research, 2018, 37, 145.	8.6	43
23	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Letters, 2020, 485, 45-55.	7.2	42
24	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. European Urology, 2019, 76, 280-283.	1.9	41
25	Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report. Urologia Internationalis, 2010, 85, 334-340.	1.3	40
26	Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. Scientific Reports, 2017, 7, 8869.	3.3	40
27	Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e17-605.e23.	1.6	39
28	New N Staging System of Penile Cancer Provides a Better Reflection of Prognosis. Journal of Urology, 2011, 186, 518-523.	0.4	37
29	Establishing Criteria for Bilateral Pelvic Lymph Node Dissection in the Management of Penile Cancer: Lessons Learned from an International Multicenter Collaboration. Journal of Urology, 2015, 194, 696-702.	0.4	37
30	The Value of Squamous Cell Carcinoma Antigen in the Prognostic Evaluation, Treatment Monitoring and Followup of Patients With Penile Cancer. Journal of Urology, 2008, 180, 2019-2023.	0.4	36
31	Performance of serum prostateâ€specific antigen isoform [â€2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospitalâ€based biopsy population. Prostate, 2014, 74, 1569-1575.	2.3	36
32	Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma. Oncology Letters, 2015, 10, 3073-3080.	1.8	36
33	External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort. Asian Journal of Andrology, 2012, 14, 738-744.	1.6	33
34	Evaluation of fine particles in surgical smoke from an urologist's operating room by time and by distance. International Urology and Nephrology, 2015, 47, 1671-1678.	1.4	33
35	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. Oncolmmunology, 2020, 9, 1762473.	4.6	33
36	Age-Dependent Association between Sex and Renal Cell Carcinoma Mortality: a Population-Based Analysis. Scientific Reports, 2015, 5, 9160.	3.3	32

#	Article	IF	CITATIONS
37	Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series. PLoS ONE, 2015, 10, e0118022.	2.5	32
38	Extent of pelvic lymph node dissection in penile cancer may impact survival. World Journal of Urology, 2016, 34, 353-359.	2.2	32
39	Targeting CPT1B as a potential therapeutic strategy in castrationâ€resistant and enzalutamideâ€resistant prostate cancer. Prostate, 2020, 80, 950-961.	2.3	31
40	Prospectively Packaged Ilioinguinal Lymphadenectomy for Penile Cancer: The Disseminative Pattern of Lymph Node Metastasis. Journal of Urology, 2009, 181, 2103-2108.	0.4	30
41	Lymph node metastases and prognosis in penile cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 90-96.	2.2	30
42	Identification and validation of an eightâ€gene expression signature for predicting high Fuhrman grade renal cell carcinoma. International Journal of Cancer, 2017, 140, 1199-1208.	5.1	29
43	Evaluation of ^{99m} Tc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian Journal of Andrology, 2017, 19, 267.	1.6	29
44	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, earlyâ€onset disease. Cancer, 2019, 125, 1060-1069.	4.1	28
45	A global approach to improving penile cancer care. Nature Reviews Urology, 2022, 19, 231-239.	3.8	28
46	Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Scientific Reports, 2016, 6, 23594.	3.3	27
47	A functional variant in <scp><i>TP</i></scp> <i>63</i> at 3q28 associated with bladder cancer risk by creating an mi <scp>R</scp> â€140â€5p binding site. International Journal of Cancer, 2016, 139, 65-74.	5.1	27
48	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 531.e7-531.e15.	1.6	27
49	Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population. Scientific Reports, 2016, 6, 21677.	3.3	26
50	Norcantharidin induces autophagy-related prostate cancer cell death through Beclin-1 upregulation by miR-129-5p suppression. Tumor Biology, 2016, 37, 15643-15648.	1.8	26
51	Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 147-152.	1.6	26
52	Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients. Oncotarget, 2015, 6, 27378-27387.	1.8	26
53	The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. Scientific Reports, 2017, 7, 9846.	3.3	25
54	Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. European Urology Focus, 2019, 5, 737-741.	3.1	25

#	Article	IF	CITATIONS
55	Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. Oncotarget, 2017, 8, 71797-71804.	1.8	25
56	Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. Oncology Letters, 2016, 11, 879-883.	1.8	24
57	Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. Journal of Urology, 2020, 203, 562-569.	0.4	24
58	Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. Oncotarget, 2016, 7, 32723-32730.	1.8	24
59	Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. International Journal of Clinical Oncology, 2016, 21, 373-378.	2.2	23
60	Elevated MRE11 expression associated with progression and poor outcome in prostate cancer. Journal of Cancer, 2019, 10, 4333-4340.	2.5	23
61	Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget, 2015, 6, 32212-32219.	1.8	23
62	SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma. Oncology Letters, 2018, 15, 4564-4570.	1.8	22
63	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. European Urology Oncology, 2021, 4, 802-810.	5.4	22
64	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. Scientific Reports, 2017, 7, 2074.	3.3	21
65	Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. Cancer Medicine, 2018, 7, 5431-5438.	2.8	21
66	Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. Oncotarget, 2017, 8, 24362-24371.	1.8	21
67	Causes of Death and Conditional Survival of Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 591.	2.8	20
68	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU International, 2020, 125, 82-88.	2.5	20
69	Prevalence of comprehensive <scp>DNA</scp> damage repair gene germline mutations in Chinese prostate cancer patients. International Journal of Cancer, 2021, 148, 673-681.	5.1	20
70	Prognostic significance of the TREK-1 K2P potassium channels in prostate cancer. Oncotarget, 2015, 6, 18460-18468.	1.8	20
71	Expression of Dicer and Its Related MiRNAs in the Progression of Prostate Cancer. PLoS ONE, 2015, 10, e0120159.	2.5	19
72	ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma. Cancer Science, 2015, 106, 687-691.	3.9	18

#	Article	IF	CITATIONS
73	Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma. Journal of Cancer, 2016, 7, 1340-1346.	2.5	18
74	Pathological Features of Localized Prostate Cancer in China: A Contemporary Analysis of Radical Prostatectomy Specimens. PLoS ONE, 2015, 10, e0121076.	2.5	18
75	A single nucleotide polymorphism in <i>ADIPOQ</i> predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. Oncotarget, 2015, 6, 32205-32211.	1.8	18
76	Comprehensive Analysis of <i>BAP1</i> Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms <i>in Silico</i> . Journal of Cancer, 2018, 9, 4108-4116.	2.5	17
77	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. Oncologist, 2020, 25, e1042-e1050.	3.7	17
78	Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer. Asian Journal of Andrology, 2019, 21, 618.	1.6	17
79	Forkhead‑box series expression network is associated with outcome of clear‑cell renal cell carcinoma. Oncology Letters, 2018, 15, 8669-8680.	1.8	16
80	Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. Frontiers in Oncology, 2019, 9, 856.	2.8	16
81	The Rare Variant rs35356162 in UHRF1BP1 Increases Bladder Cancer Risk in Han Chinese Population. Frontiers in Oncology, 2020, 10, 134.	2.8	16
82	Visceral fat accumulation is associated with different pathological subtypes of renal cell carcinoma (<scp>RCC</scp>): a multicentre study in <scp>C</scp> hina. BJU International, 2014, 114, 496-502.	2.5	15
83	Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. Scientific Reports, 2015, 5, 15341.	3.3	15
84	Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a SEER analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 288-295.	1.5	15
85	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. Scientific Reports, 2017, 7, 7587.	3.3	15
86	Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology, 2017, 109, 140-144.	1.0	15
87	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with nodeâ€positive penile squamous cell carcinoma. BJU International, 2020, 125, 867-875.	2.5	15
88	Population-Based Assessment of the Number of Lymph Nodes Removed in the Treatment of Penile Squamous Cell Carcinoma. Urologia Internationalis, 2014, 92, 186-193.	1.3	14
89	Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines. Annals of Surgical Oncology, 2019, 26, 685-691.	1.5	14
90	The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients. Annals of Surgical Oncology, 2019, 26, 653-659.	1.5	14

#	Article	IF	CITATIONS
91	Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma. Journal of Cancer, 2017, 8, 3490-3497.	2.5	13
92	Inherited Mutations in Chinese Men With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 54-62.	4.9	13
93	Surgical treatment of primary disease for penile squamous cell carcinoma: A Surveillance, Epidemiology, and End Results database analysis. Oncology Letters, 2015, 10, 85-92.	1.8	12
94	Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib. Oncotarget, 2016, 7, 26879-26887.	1.8	12
95	Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population. Scientific Reports, 2016, 6, 36264.	3.3	12
96	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. Translational Andrology and Urology, 2017, 6, 848-854.	1.4	12
97	Lowâ€serum prostateâ€specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate, 2019, 79, 1563-1571.	2.3	12
98	Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. Prostate Cancer and Prostatic Diseases, 2020, 23, 197-198.	3.9	12
99	A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU International, 2020, 126, 577-585.	2.5	12
100	<p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)</p> . Cancer Management and Research, 2020, Volume 12, 2127-2140.	1.9	12
101	PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway. PLoS ONE, 2017, 12, e0180862.	2.5	12
102	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. European Urology Oncology, 2022, 5, 420-427.	5.4	12
103	Prostate cancer and prostatic diseases Best of China, 2018. Prostate Cancer and Prostatic Diseases, 2019, 22, 1-2.	3.9	11
104	Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China. European Urology, 2020, 78, 120-122.	1.9	11
105	Validation of the prognostic value of lymph node ratio in patients with penile squamous cell carcinoma: a population-based study. International Urology and Nephrology, 2013, 45, 1263-1271.	1.4	10
106	Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Scientific Reports, 2017, 7, 43551.	3.3	10
107	Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. Scientific Reports, 2018, 8, 374.	3.3	10
108	Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry. Oncotarget, 2015, 6, 44955-44962.	1.8	10

#	Article	IF	CITATIONS
109	Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian Journal of Andrology, 2016, 18, 633.	1.6	10
110	Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?. OncoTargets and Therapy, 2014, 7, 2043.	2.0	9
111	Smoking increased the risk of prostate cancer with grade group ≥ 4 and intraductal carcinoma in a prospective biopsy cohort. Prostate, 2017, 77, 984-989.	2.3	9
112	National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients. Asian Journal of Andrology, 2018, 20, 551.	1.6	9
113	Relationship between PSA kinetics and Tcâ€99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Prostate, 2018, 78, 1215-1221.	2.3	9
114	Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study. Frontiers in Oncology, 2020, 10, 1521.	2.8	9
115	Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer. Journal of Cancer, 2020, 11, 997-1007.	2.5	9
116	Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort. Oncotarget, 2015, 6, 22978-22984.	1.8	9
117	External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. Asian Journal of Andrology, 2018, 20, 184.	1.6	9
118	Genetic variants in insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men. OncoTargets and Therapy, 2016, 9, 61.	2.0	8
119	Prognosis of rare pathological primary urethral carcinoma. Cancer Management and Research, 2018, Volume 10, 6815-6822.	1.9	8
120	A single nucleotide polymorphism in CYP1B1 leads to differential prostate cancer risk and telomere length. Journal of Cancer, 2018, 9, 269-274.	2.5	8
121	Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing. Oncogene, 2021, 40, 2382-2394.	5.9	8
122	Outcomes of perineal urethrostomy for penile cancer: A 20-year international multicenter experience. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 500.e9-500.e13.	1.6	8
123	Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer. Kaohsiung Journal of Medical Sciences, 2014, 30, 82-85.	1.9	7
124	Preneoplastic and Primary Scrotal Cancer. Urologic Clinics of North America, 2016, 43, 523-530.	1.8	7
125	MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai. Scientific Reports, 2016, 6, 36290.	3.3	7
126	Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. Journal of Cancer, 2019, 10, 6170-6174.	2.5	7

#	Article	IF	CITATIONS
127	Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study. Asian Journal of Andrology, 2021, 23, 41.	1.6	7
128	Combination of body mass index and albumin predicts the survival in metastatic castrationâ€resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. Cancer Medicine, 2021, 10, 6697-6704.	2.8	7
129	Association of glutathione S-transferase T1 and M1 polymorphisms with prostate cancer susceptibility in populations of Asian descent: a meta-analysis. Oncotarget, 2015, 6, 35843-35850.	1.8	7
130	External validation of nomograms for predicting cancer-specific mortality in penile cancer patients treated with definitive surgery. Chinese Journal of Cancer, 2014, 33, 249-255.	4.9	7
131	Alkaline phosphatase velocity in nonmetastatic CRPC. Nature Reviews Urology, 2014, 11, 666-667.	3.8	6
132	Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. World Journal of Surgical Oncology, 2015, 13, 172.	1.9	6
133	Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph nodeâ€'metastatic penoscrotal extramammary Paget's disease. Oncology Letters, 2019, 17, 2677-2686.	1.8	6
134	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 879.	2.8	6
135	Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. International Urology and Nephrology, 2020, 52, 87-95.	1.4	6
136	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. Frontiers in Oncology, 2020, 10, 527952.	2.8	6
137	Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Oncotarget, 2016, 7, 68943-68953.	1.8	6
138	Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study. World Journal of Surgical Oncology, 2015, 13, 132.	1.9	5
139	Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Scientific Reports, 2016, 6, 19034.	3.3	5
140	Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility. Carcinogenesis, 2017, 38, 1241-1248.	2.8	5
141	Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy. PLoS ONE, 2017, 12, e0187887.	2.5	5
142	Evaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancer. World Journal of Urology, 2018, 36, 769-774.	2.2	5
143	Preoperative prostate health index predicts poor pathologic outcomes of radical prostatectomy in patients with biopsy-detected low-risk patients prostate cancer: results from a Chinese prospective cohort. Prostate Cancer and Prostatic Diseases, 2018, 21, 64-70.	3.9	5
144	The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. European Urology Focus, 2020, 6, 53-62.	3.1	5

#	Article	IF	CITATIONS
145	>Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy. Cancer Management and Research, 2020, Volume 12, 1779-1787.	1.9	5
146	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. European Urology Oncology, 2021, 4, 121-123.	5.4	5
147	Clinical significance of TMPRSS4 in prostate cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 8053-8.	0.5	5
148	Clinical significance of urine prostatic exosomal protein in the diagnosis of prostate cancer. American Journal of Cancer Research, 2019, 9, 1074-1078.	1.4	5
149	Prognostic value of carbonic anhydrase IX expression in penile squamous cell carcinoma: A pilot study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 706-711.	1.6	4
150	Two novel <i>PRKCI</i> polymorphisms and prostate cancer risk in an Eastern Chinese Han population. Molecular Carcinogenesis, 2015, 54, 632-641.	2.7	4
151	Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab. Medical Science Monitor, 2019, 25, 6518-6522.	1.1	4
152	Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 713.	2.0	3
153	PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 500-505.	1.5	3
154	Preliminary results of targeted prostateâ€specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castrationâ€resistant prostate cancer. Cancer Medicine, 2020, 9, 3278-3286.	2.8	3
155	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e7-838.e13.	1.6	3
156	Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 514-514.	1.6	2
157	A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort. Frontiers in Oncology, 2021, 11, 753920.	2.8	2
158	High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma. Journal of Cancer, 2018, 9, 3400-3406.	2.5	1
159	Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2019, 5, 745-747.	3.1	1
160	Identification of a methylation panel aid in risk stratification in nodeâ€positive penile squamous cell carcinoma. International Journal of Cancer, 2021, 148, 1289-1298.	5.1	1
161	Impact of radiation therapy on perineal urethrostomy for penile cancer. Clinical and Translational Radiation Oncology, 2021, 30, 84-87.	1.7	1
162	Locoregional surgical treatment improves the prognosis in patients with primary metastatic testicular cancer with a single bone or brain metastasis. Molecular and Clinical Oncology, 2020, 13, 146-154.	1.0	1

#	Article	IF	CITATIONS
163	Genetic variants in telomere-maintenance genes and bladder cancer risk. Chinese-German Journal of Clinical Oncology, 2013, 12, 448-453.	0.1	0
164	Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib. Future Oncology, 2016, 12, 1783-1793.	2.4	0
165	Prognosis of the Metachronous and Synchronous Bilateral Renal Cancer and Second Primary Cancer After the Bilateral Renal Cancer: a Population-Based Analysis. SN Comprehensive Clinical Medicine, 2019, 1, 900-904.	0.6	0
166	ASO Author Reflections: T1b Penile Cancer: An Alarm to Improve Treatment. Annals of Surgical Oncology, 2019, 26, 692-693.	1.5	0
167	Germline DNA damage repair gene alterations in Chinese prostate patients: More than HRR and MMR Journal of Clinical Oncology, 2019, 37, e13041-e13041.	1.6	0
168	Development of a risk calculator of recurrence in inguinal lymph node metastatic (ILNM) patients with surgically resected penile squamous cell carcinoma (PSCC) Journal of Clinical Oncology, 2020, 38, 1-1.	1.6	0
169	Regression tree analysis to identify the best candidates for neoadjuvant chemotherapy (NAC) in patients with clinically lymph node-positive penile squamous cell carcinoma (PSCC) Journal of Clinical Oncology, 2020, 38, 2-2.	1.6	0
170	Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.02.010. European Urology, 2022	1.9	0
171	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. Eur Urol Oncol. In press.	5.4	0

https://doi.org/10.1016/j.euo.2022.04.005. European Urology Oncology, 2022.